Jafron Biomedical Co.,Ltd. (SHE:300529)

Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,312	2,670	1,919	2,487	2,671	1,946
Other Revenue	4.3	7.33	3.42	4.54	4.5	4.64
Revenue	2,316	2,677	1,922	2,491	2,675	1,951
Revenue Growth (YoY)	-3.73%	39.27%	-22.84%	-6.88%	37.15%	36.24%
Cost of Revenue	464.28	520.26	390.89	440.36	402.12	288
Gross Profit	1,852	2,157	1,531	2,051	2,273	1,663
Selling, General & Admin	780.74	881.19	787.89	838.78	729.46	587.45
Research & Development	224.76	240.09	245.38	253.91	173.77	80.76
Other Operating Expenses	64.42	37.29	24.61	33.72	39.56	28.24
Operating Expenses	1,066	1,159	1,048	1,124	949.55	697.27
Operating Income	786.25	997.98	482.98	926.66	1,324	965.51
Interest Expense	-57.98	-63.71	-54.33	-36.04	-8.91	-
Interest & Investment Income	55.68	73.09	87.96	63.79	56.5	44.01
Currency Exchange Gain (Loss)	0.32	0.78	1.22	1.07	-0.81	-0.37
Other Non Operating Income (Expenses)	20.34	-1.73	-2.12	-0.5	-5.34	-2.36
EBT Excluding Unusual Items	804.62	1,006	515.71	954.97	1,365	1,007
Impairment of Goodwill	-5.2	-5.2	-25.61	-6.26	-	-
Gain (Loss) on Sale of Investments	16.77	1.02	-	-0.01	0.01	-
Gain (Loss) on Sale of Assets	0.06	3.64	6.72	0.86	0.98	-
Asset Writedown	-1.47	-1.04	-1.46	-1.61	-1.15	-0.48
Other Unusual Items	-6.17	2.13	25.66	68.85	42.14	25.64
Pretax Income	808.62	1,007	521.02	1,017	1,407	1,032
Income Tax Expense	156.52	192.78	95.3	135.86	211.38	158.95
Earnings From Continuing Operations	652.1	814.19	425.72	880.95	1,196	873
Minority Interest in Earnings	5.31	6.01	10.77	8.62	0.97	2.24
Net Income	657.41	820.2	436.49	889.56	1,197	875.24
Net Income to Common	657.41	820.2	436.49	889.56	1,197	875.24
Net Income Growth	-7.60%	87.91%	-50.93%	-25.67%	36.74%	53.33%
Shares Outstanding (Basic)	763	781	794	794	803	796
Shares Outstanding (Diluted)	773	781	794	794	803	810
Shares Change (YoY)	-3.13%	-1.57%	-0.08%	-1.12%	-0.89%	2.22%
EPS (Basic)	0.86	1.05	0.55	1.12	1.49	1.10
EPS (Diluted)	0.85	1.05	0.55	1.12	1.49	1.08
EPS Growth	-4.61%	90.91%	-50.89%	-24.83%	37.96%	50.00%
Free Cash Flow	644.15	815.85	669.49	407.91	712	600.37
Free Cash Flow Per Share	0.83	1.04	0.84	0.51	0.89	0.74
Dividend Per Share	0.800	0.800	0.400	0.670	0.900	0.660
Dividend Growth	100.00%	100.00%	-40.30%	-25.56%	36.36%	39.33%
Gross Margin	79.95%	80.57%	79.67%	82.33%	84.97%	85.24%
Operating Margin	33.95%	37.28%	25.12%	37.19%	49.48%	49.49%
Profit Margin	28.38%	30.64%	22.71%	35.70%	44.73%	44.87%
Free Cash Flow Margin	27.81%	30.47%	34.83%	16.37%	26.61%	30.78%
EBITDA	910.06	1,120	573.43	995.72	1,373	1,002
EBITDA Margin	39.29%	41.82%	29.83%	39.97%	51.32%	51.38%
D&A For EBITDA	123.8	121.69	90.44	69.07	49.25	36.73
EBIT	786.25	997.98	482.98	926.66	1,324	965.51
EBIT Margin	33.95%	37.28%	25.12%	37.19%	49.48%	49.49%
Effective Tax Rate	19.36%	19.14%	18.29%	13.36%	15.02%	15.40%
Revenue as Reported	2,316	2,677	1,922	2,491	2,675	1,951

Source: S&P Global Market Intelligence. Standard template. Financial Sources.